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Food for Thought … 
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1Johns Hopkins University, Bloomberg School of Public Health, CAAt, Baltimore, USA; 2University of Konstanz,  
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Introduction
Countermeasures evaluation is the new kid on the block of al-
ternative approaches. And it is a big kid that appeared suddenly: 
Over the last six months three funding opportunities in the US 
totaled more than $ 200 million, all with the goal of advancing 
the Human on a Chip concept. An alliance of US agencies is 
tackling the problem of evaluating drugs for which there are 
no patients and, hopefully, never will be patients. three dif-
ferent calls from NIH, FDA, and the Department of Defense 
(DoD) agencies, DtRA (Defense threat Reduction Agency) 
and DARPA (Defense Advanced Research Agency), all aim for 
producing a number of three-dimensional human organ equiva-
lents based on stem cell technology and combining them with 
microfluidics on a chip. The design criteria for the two consortia 
sponsored by DARPA/FDA1, with about $ 35 million each, are 
very demanding: 10 organs to be maintained for 4 weeks. the 
projects supported by NIH/FDA2 will develop individual 3D 
organ equivalents to opt into the platforms established in the 
former call. It is the first time that DARPA and NIH have teamed 
up, with each agency committing $ 70 million. the NIH con-
tribution will come from its director’s discretionary “Common 
Fund” but will be administered through the new National Center 
for Advancing translational Sciences (NCAtS)3. the FDA will 
advise the agencies on how to meet its requirements for safety 
and effectiveness as part of their medical countermeasure initia-
tive4. DtRA seeks independently 5 “a platform comprised of in 
vitro human organ constructs in communication with each other 
[(i.e., liver, lung, heart, kidney, vasculature, and Blood Brain 
Barrier (BBB) with neuronal component] that will accurately 
assess efficacy, toxicity, and pharmacokinetics of drugs in a way 
that is relevant to humans.” 
the activities are prompted by the perceived need to have 
medical countermeasures (MCM) at hand in case something 
happens. (Note, however, that the eU does not follow the same 
path.) the obvious problem is the lack of patients for clini-
cal development, which make a traditional product registration 
with FDA impossible. the original response was the Animal 
Rule, i.e., the suggestion to use appropriate animal models in-
stead. In May 2002, FDA issued the final rule New Drug and 
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The desire to develop and evaluate drugs as potential countermeasures for biological and chemical  
threats requires test systems that can also substitute for the clinical trials normally crucial for drug 
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Consideration 1:  
There is no such thing as a sufficiently predictive 
animal model for countermeasures
the US Department of Defense sponsored a National Academy 
of Sciences report, Animal Models for Assessing Countermeas-
ures to Bioterrorism Agents, published in December 20118. One 
author (tH) had the privilege of being part of the committee. 
The key findings of the report are reproduced in Box 2. In a nut-
shell, neither animal nor alternative methods are available for 
this purpose, but the committee discouraged the development of 
further animal models while proposing the exploitation of new 
alternative approaches.
Biological Drug Products; Evidence Needed to Demonstrate 
Effectiveness of New Drugs When Human Efficacy Studies Are 
Not Ethical or Feasible6 (Kwik et al. 2007). FDA’s own sum-
mary of the animal rule is reproduced in Box 1. In a nutshell, 
FDA allows substituting for evidence of efficacy (not safety!) 
in humans with animal studies if a “reasonably well under-
stood pathophysiological mechanism for the toxicity … and 
its amelioration or prevention by the product” is given, “ef-
fect is demonstrated in more than one animal species” or “a 
single animal species … predicting the response in humans,” 
“study endpoint is … generally the enhancement of survival 
or prevention of major morbidity,” and “pharmacokinetics and 
pharmacodynamics … in animals and humans is sufficiently 
well understood.”
It appears that the obvious non-fit for purpose of animal mod-
els paired with the need to regulate these new products opens 
doors for new approaches. this is very reminiscent of the intro-
duction of the limulus assay (lAl) in 1986 by FDA, when the 
duration of the rabbit assay did simply not allow testing short-
lived radiopharmaceuticals. Once introduced, the lAl became 
broadly applied, making it probably the most successful alterna-
tive method to date. Similarly, FDA’s new interest in predictive 
in vitro tools for MCM might be a door-opener for the evalua-
tion of drugs in general.
6 http://www.gpo.gov/fdsys/pkg/FR-2002-05-31/pdf/02-13583.pdf
7 Taken from the introduction in the final regulation, New Drug and Biological Drug Products; Evidence Needed to 
Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible, Federal Register,  
Vol. 67, No. 105, Friday, May 31, 2002, https://federalregister.gov/a/02-13583. Last accessed, June 21, 2012. 
8 http://dels.nationalacademies.org/Report/Animal-Models-Assessing-Countermeasures/13233
Box 1
FDA Animal Rule Summary 7
In assessing the sufficiency of animal data, the agency may 
take into account other data, including human data, avail-
able to the agency. Under this rule, FDA can rely on the evi-
dence from animal studies to provide substantial evidence 
of the effectiveness of these products when:
1. there is a reasonably well understood pathophysiologi-
cal mechanism for the toxicity of the chemical, biologi-
cal, radiological, or nuclear substance and its ameliora-
tion or prevention by the product;
2. the effect is demonstrated in more than one animal spe-
cies expected to react with a response predictive for hu-
mans, unless the effect is demonstrated in a single animal 
species that represents a sufficiently well characterized 
animal model (meaning the model has been adequately 
evaluated for its responsiveness) for predicting the re-
sponse in humans;
3. the animal study endpoint is clearly related to the de-
sired benefit in humans, which is generally the enhance-
ment of survival or prevention of major morbidity; and
4. the data or information on the pharmacokinetics and 
pharmacodynamics of the product or other relevant data 
or information in animals and humans is sufficiently 
well understood to allow selection of an effective dose 
in humans, and it is therefore reasonable to expect the 
effectiveness of the product in animals to be a reliable 
indicator of its effectiveness in humans.
All studies subject to this rule must be conducted in accord-
ance with preexisting requirements under the good labora-
tory practices (21 CFR part 58) regulations and the Animal 
Welfare Act (7 U.S.C. 2131 et seq.). Safety evaluation of 
products is not addressed in this rule. Products evaluated 
for effectiveness under subpart I of part 314 and subpart H 
of part 601 will be evaluated for safety under preexisting 
requirements for establishing the safety of new drug and 
biological products.
the agency believes that the safety of most of these 
products can be studied in human volunteers similar to 
the people who would be exposed to the product. FDA 
recognizes that some safety data, such as data on pos-
sible adverse interactions between the toxic substance 
itself and the new product, may not be available. this 
is not expected to keep the agency from making an ad-
equate safety evaluation. FDA’s procedures and stand-
ards for evaluating the safety of new drug and biologi-
cal products are sufficiently flexible to provide for the 
safety evaluation of products evaluated for efficacy under  
21 CFR subpart I of part 314 and subpart H of part 601. 
this rule will not apply if product approval can be based 
on standards described elsewhere in our regulations (e.g., 
accelerated approval based on human surrogate markers or 
clinical endpoints other than survival or irreversible mor-
bidity).
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this judgment is remarkable, coming unanimously from such 
an esteemed institution as the National Academies. It extends 
the earlier report, Toxicity Testing for the 21st Century: A Vision 
and a Strategy9, to drug development, in the sense that, after 
taking stock of the state of the art of animal-based evaluations, 
a call is made for novel approaches based on today’s biotech-
nology. though the committee had no mandate to discuss the 
animal rule, it effectively called for the development of a new 
approach. Similarly, we might apply this thinking to challenge 
current animal-based drug development more generally. this is 
quite in line with the ongoing devaluation of preclinical drug 
evaluation, giving rise to explorative human trials (Robinson, 
2007; Coleman, 2011), orphan drug development (Bashaw and 
Fang, 2012), microdosing (Garner, 2005; Boyd and lalonde, 
2007; lappin and Garner, 2008), etc. 
A critical point of comparison for the evaluation of MCM is 
the regular drug development process to understand the proba-
bilities of arriving, finally, at a safe and efficient drug. The com-
plete process – from drug discovery to FDA approval – takes 
an average of 10 to 15 years and costs more than $ 1 billion 
(Mundae and Ostör, 2010; tamimi and ellis, 2009; Gilbert et 
al., 2003). In some estimates, when the costs of failed prospec-
tive drugs are factored in, the cost of a single drug development 
Box 2
Key Findings NAS report Animal  
Models for Assessing Countermeasures  
to Bioterrorism Agents (NRC, 2011)
• Currently available animal models are imperfect repre-
sentations of the human-pathogen interaction with sev-
eral important limitations, such as methodological differ-
ences and a lack of sufficient human data and knowledge 
of the natural history of diseases of interest. However, at 
this time animal models remain central to the develop-
ment of countermeasures against biothreats when testing 
the efficacy of therapeutics or vaccines would otherwise 
involve exposing human volunteers or warfighters to a 
potentially lethal or permanently disabling toxic sub-
stance or microorganism.
• Because animal models may be imperfect for a specific 
need and are expensive to employ (they require large 
numbers of animals and must be used in secure biocon-
tainment facilities), current models should be reevaluated 
for their limitations as well as their presumed advantages. 
For example, methodological differences among similar 
animal models may result in differences in how well 
those models accurately mirror the human response to 
infection or treatment. Consequently, expanded collec-
tion and analysis of human clinical data from natural in-
fections could help verify and augment the strengths of 
available models.
• Developing new animal models for biodefense research 
cannot adequately resolve in a reasonable time frame the 
limitations of the currently available ones. It would be 
more useful for transformational Medical technologies 
to support a more thorough qualification of currently 
available animal models to advance the predictive capac-
ity of animal-derived data than to create new models.
• In vitro and in silico methods are not yet advanced enough 
(in part due to the absence of human data) to reliably re-
place animals in biodefense research on a large scale.
• the Committee suggests that transformational Medi-
cal technologies undertake an analysis of the discovery, 
development, and approval process for medical counter-
measures to identify:
– Scientific gaps in terms of utilizing alternative meth-
ods to animal models and how to address them
– Specific areas in which use of in vitro and in silico 
methods could be sufficient, or an adjunct, to the use 
of animals
– Criteria for choosing and utilizing the most suitable 
technologies to replace animal use in biodefense re-
search in the near future
• Changing the standard practice of animal experimenta-
tion where feasible to approximate the clinical course of 
treatment for humans could provide a more reasonable 
prediction of the usefulness of countermeasures during 
the development process.
• Potential advances in knowledge regarding biothreats 
and medical countermeasures should be weighed against 
the duration and severity of animal pain and distress.
• A comprehensive strategy to improve the gathering and 
sharing of data from animal models (and their alterna-
tives) would significantly increase the efficiency and 
productivity of research into bioterrorism countermeas-
ures as well as improve laboratory animal welfare, if it 
includes:
– Compartmentalization – experiments designed to yield 
information from components of the animals (organs, 
cells, and systems) rather than data derived from the 
whole organism;
– the use of systems biology and in vitro or in silico 
methods;
– Systemic collection of, and access to, experimental 
data;
– Publication of negative results;
– enhanced collection and analysis of human data;
– Added clinical veterinary care.
• Where possible, transformational Medical technologies 
should encourage efforts to replace nonhuman primates 
as the animal of choice in biodefense research. Such ef-
forts, coupled with unhindered access to data and pub-
lishing of all results – even negative ones – help ensure 
that these data are beneficial, animals are used judicious-
ly, and unnecessary duplication of work is avoided.
9 free PDF available at: http://www.nap.edu/catalog.php?record_id=11970
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predictivity is not that of a single animal model but rather of the 
combination of all efforts of preclinical development. 
Sepsis, as an uncontrolled systemic infection with high mor-
tality, is a clinical condition most closely reflecting the clini-
cal features of a bioterroristic agent’s clinical picture. Buras et 
al. summarized their value as follows: “Animal models have 
been developed in an effort to create reproducible systems for 
studying sepsis pathogenesis and preliminary testing of poten-
tial therapeutic agents. However, demonstrated benefit from a 
therapeutic agent in animal models has rarely been translated 
into success in human clinical trials.” Buras et al. (2005) also 
give reasons for the difficulties of the bacterial infection models 
used. 
“Caveats of sepsis animal models…
Bacterial infection
• Requires growth and quantification of bacteria prior to 
administration
• Significant inter-laboratory variability
• Large quantity of bacteria used may elicit confounding 
toxicosis response
• Host response is dependent on infecting bacterial strain
• Different host responses with infection of different com-
partments
• Variable host response dependent on bacterial load and 
infusion time
• Genetic background affects host responses to specific 
pathogens
• Human therapy potentially withheld could detract from 
validity of therapeutic agent
Variability factors…
Bacterial infection models
• Bacterial load 
• Route of administration 
• Timing of infusion 
• Bacterial strain 
• Host strain 
• Antibiotics/fluid resuscitation”
Similarly, Opal and Cross (1999) summarize: “It has become 
painfully evident that animal models provide misleading and 
overly optimistic estimates of the survival benefit of specific an-
tisepsis drugs when compared to clinical efficacy in actual hu-
man sepsis.” the clinical studies in sepsis following the success-
ful completion of preclinical animal models was summarized by 
Opal and Cross (1999): “Since 1982, the field of clinical sepsis 
research has suffered a long series of failed clinical trials that 
studied new treatment strategies for septic shock. Over 13,000 
patients have been enrolled in at least 23 multicenter, double-
blind, placebo-controlled, clinical trials in an attempt to devel-
op new treatments for septic shock. Unfortunately, the results 
have been generally disappointing and interspersed with some 
has soared from $ 1.1 billion in 1995 to $ 1.7 billion in 2002. 
The figures are not very different for biopharmaceuticals com-
pared to small molecules (DiMasi and Grabowski, 2007). 
typically, MCM can be developed until phase I clinical trials, 
so the point of comparison needs to be the clinical development 
phase and its success/attrition rate. Approximately 8% of drugs 
that now enter phase I studies eventually become FDA approved 
products, compared to 14% in the eighties10. the success rates 
from the first study in humans to launch are now <10% (Peck, 
2007), according to the C.M.R. International 2006/7 Pharma-
ceutical R&D Factbook cited. the attrition rate in phase II is 
now more than 70% and rising, and even in phase III one-third 
to half the molecules fail (Kola and landis, 2004; DiMasi, 
2001a)11. Obviously, recent biomedical research breakthroughs 
have not improved our ability to identify successful candidates. 
the main causes of failure in the clinic include safety prob-
lems (about 20%) and lack of effectiveness (about 40%), both 
predicted by a series of animal models before entering the most 
costly part of drug development. the inability to predict these 
failures before human testing or early in clinical trials dramati-
cally escalates costs. In the infectious disease area, data from the 
ten biggest drug companies during 1991-2000 showed a success 
rate of about 15%, while the average of all indications was 11% 
(DiMasi and Grabowski, 2007). Similarly, DiMasi et al. (2010) 
showed a success rate for systemic infectious disease of 15.6% 
during 1994 and 2003. Noteworthy, from 1981 to 1992 the suc-
cess rate of anti-infective drugs was 28.1% (DiMasi, 2001b). 
Overall, biopharmaceuticals appear to have the higher success 
rate (all indications) of 30.2% (Gilbert et al., 2003).
A key question, then, is whether countermeasures to bioter-
rorism have a higher likelihood of success in a (theoretical) hu-
man trial? A number of aspects actually argue against this, as 
summarized by one author (tH) for the NAS report:
– the type of diseases are peracute systemic infections, most 
closely related to sepsis patients, a disease entity most notori-
ous in failing clinical trials (see below).
– the pathogenesis of these rare or even unknown diseases is 
little known to guide the development process.
– the pathogens are likely to be optimized to stand interven-
tions, e.g., by introduced antibiotic resistance.
– the clinical setting is likely one of mass infection, possibly 
combined with other threats, hardly comparable to the rand-
omized clinical trials of hospitalized patients.
– the biosafety levels and the strong reliance on non-human 
primates limit the number of animal studies. 
– Most development took place with less than average develop-
ment expenditure by entities not experienced with full clinical 
development of drugs. 
It must be concluded that a success rate of normal drug devel-
opment can only be used as a best-case scenario. Note that this 
10 Food and Drug Administration, Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New 
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spectacular failures and unexpected toxicities.” Opal updated 
these data for 2009 in his presentation to the committee report-
ing that 42 clinical studies led to 39 cases of lack of effect, one 
small effect, and two cases where the situation of the patients 
worsened (Christaki et al., 2011). 
In conclusion, it must be assumed that the likelihood of suc-
cess in humans of countermeasures to bioterrorism would be 
considerably lower than the average 11% success rate of drugs 
at a similar stage of development. there is no evidence that any 
additional animal model would improve such a success rate. 
this is especially apt if this animal model represents a repeti-
tion of a model used during the development process: In fact, it 
would be rather unlikely that a most promising animal model 
would not have been used during the development process and 
left for the final phase of the clinical trial equivalent. 
Consideration 2:  
Complexity versus simplicity in modeling  
complex biology
the Human on a Chip concept aims for the combination of 
human stem cell-based 3D organ systems to be combined in 
a microfluidic platform. This combines a number of desirable 
features:
1) Organotypic coculture of cells: the concept of mirroring the 
complexity of the organism in the test models is appealing. 
the coculture of cells allows for cellular interactions and 
mutual influences for cell development and differentiation. 
However, achieving natural proportions of cell types and tis-
sue architecture is a major challenge.
2) 3D systems: the third dimension adds another physiologic 
component. While traditional cell cultures have only 1% of 
the cell density of tissue and less than 10% of normal cell-
cell-contacts (Hartung, 2007a), 3D models reflect the tissue 
situation but pose a problem of nutrient and oxygen supply 
in the absence of a circulatory system and hemoglobin.
3) Perfusion: While traditional cell culture does not achieve 
homeostasis but is characterized by repeated exchange of 
culture media with an interim decrease in nutrients and accu-
mulation of waste products, cell perfusion culture can main-
tain stable conditions. However, stable conditions are not yet 
physiological conditions and, typically, large culture media 
volumes are needed. If recirculating the medium, volumes 
can be reduced but stability of media composition is reduced 
if no regulated nutrient supply and excretion systems are built 
in. One author (tH) had early experiences in two eU-funded 
consortia for perfused cultures of kidney and liver (Koppel-
staetter et al., 2004; Jennings et al., 2004). these taught us 
the advantages of such systems but also the difficulties in 
standardization, long-term maintenance, throughput, etc.
4) Human stem-cell based systems: It is a common assumption 
that human cells reflect human reactivity better than animal 
cells. though experimental evidence is rather limited, it is 
certainly wise to work with cells from one species, prefer-
ably humans. Studies in human versus mouse bone marrow 
(Pessina et al., 2003) suggest that human reactivity is indeed 
reflected on an in vitro level to an extent that species differ-
ences in vivo can be estimated. In the same vein, the MeIC 
study, which tested 50 reference compounds in 61 in vitro 
assays, showed the best predictivity of human lethal plasma 
concentrations with human cells (ekwall, 1999). Stem cells 
promise to be a resource of human quasi-primary cells, but 
we should keep in mind that we do not currently have proto-
cols for final differentiation of most cell types (with the ex-
ception of cardiomyocytes), and the generation of pure cell 
types is still beyond reach.
5) Chip-based systems: they combine both miniaturization 
(few cells and little test agent) and opportunities for continu-
ous measurements (Khetani and Bhaita, 2006; Ni et al., 2009; 
Zhang et al., 2009; Gupta et al., 2010; Shintu et al., 2012). 
Promising examples exist (van Vliet et al., 2007; Huh et al., 
2010; Robinette et al., 2011), some of which use functional 
endpoints to predict hazards. At this juncture, however, it is 
mainly electrophysiology that allows continuous measure-
ment but limits us to neurons and cardiomyocytes. Unspe-
cific measurements such as impedance are on the way, but 
continuous functional markers are rare. 
As appealing as a combination of so many good things is (“Too 
much of a good thing is wonderful,” Mae West), the question 
emerges whether the enormous efforts to create such systems 
are necessary to predict human reactions. Challenges include:
– Final differentiation of stem cells to the different cell types of 
the organ, including drug metabolism capacity. 
– Finding compromise cell culture conditions to maintain all 
the different cells and organ equivalents.
– Balancing organ equivalent sizes and the perfusion liquid 
compartment to allow close to physiological kinetics.
– Continuous supply with nutrients and oxygen as well as ex-
traction of waste products.
– Biocompatible materials for all cell types supporting but not 
interfering with differentiation.
– Sufficiently noninvasive measurements for the small amounts 
of cells on a chip and the kinetics of the test substance.
this is not just an engineering challenge but also a standardiza-
tion and reproducibility challenge. A key lesson from the valida-
tion of alternative methods (Hartung, 2010a) is the pivotal role 
of this challenge, and usually this requires simplicity. the more 
variables in a system, the more standardization is required and 
the more opportunities for introducing variability. 
Consideration 3:  
Three things count for the new tools for MCM: 
quality, quality, and quality
Cell cultures are prone to artifacts (Hartung, 2007a): Far too 
many artificially chosen and difficult to control conditions influ-
ence our experiments. Quality assurance is the gift from alterna-
tive methods to the life sciences. this blunt statement might be 
challenged by those involved with Good laboratory Practice 
(GlP) or ISO quality assurance. However, while GlP (at least 
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ences: GlP still gives only limited guidance for in vitro. GlP 
cannot normally be implemented in academia on the grounds 
of costs and lack of flexibility. GCCP, on the other hand, also 
aims to give guidance to journals and funding bodies. Note that 
guidance also has been developed for the publication of in vitro 
journal articles (leist et al., 2010). A CAAt workshop was held 
in March 2012 in San Francisco, and a taskforce was formed to 
further this work.
All quality assurance of an in vitro system starts with its defi-
nition and standardization, which include:
– A definition of the scientific purpose of the method
– A description of its mechanistic basis 
– the case for its relevance 
– the availability of an optimized protocol, including:
- standard operation procedures
- specification of endpoints and endpoint measurements
- derivation, expression, and interpretation of results (prelimi-
nary prediction model)
- the inclusion of adequate controls
– An indication of limitations (preliminary applicability do-
main)
– Quality assurance measures
the novel types of Human on a Chip test will represent ad-
ditional challenges as to standardization of design and genera-
tion of cultures and devices. the systems are considerably more 
complex than traditional in vitro approaches, involving various 
cell types and engineering.
this standardization forms the basis for formal validation, as 
developed by eCVAM, adapted and expanded by ICCVAM and 
other validation bodies, and, finally, internationally harmonized 
by OeCD (OeCD, 2005). Validation is the independent assess-
ment of the scientific basis, the reproducibility, and the predic-
tive capacity of a test. It was redefined in 2004 in the Modu-
lar Approach (Hartung et al., 2004) but needs to be seen as a 
continuous adaptation of the process to practical needs and a 
case-by-case assessment of what is feasible (Hartung, 2007b; 
leist et al., 2012). the most important changes to the Modu-
lar Approach were: the introduction of an applicability domain 
(borrowing the concept from QSAR), the use of existing data 
(retrospective validation), the independence of reproducibility 
and relevance assessment, allowing leaner study designs and 
performance standards for similar tests to be considered equiva-
lent to a validated one. 
Applicability domain describes the range of test materials to 
which the test can be applied and reliable predictions obtained 
(e.g., which chemical class(es), types of products). A later 
change in, or extension of, the applicability domain might re-
quire additional validation work and a new peer-review. While 
earlier validation studies had not taken into consideration any 
existing data on a test, the introduction of retrospective valida-
tion allowed for their use as sole source or in combination with 
prospective data generation. traditional validation studies need 
a certain number of test items in at least three labs to assess 
both reproducibility and relevance. Often, however, fewer test 
items are required to establish reproducibility, allowing the test-
ing of further items in one laboratory only once reproducibility 
has been confirmed, which can eliminate half the testing with-
originally) addressed only regulatory in vivo studies, and ISO 
guidance is not really specific for life science tools, neither ad-
dresses the key issue, i.e., the relevance of a test. this is the 
truly unique contribution of validation, which is far too rarely 
applied in other settings.
the limited applicability of GlP to in vitro studies was first 
addressed in an eCVAM workshop in 1998 (Cooper-Hannan 
et al., 1999). Parallel initiatives involving one author (tH) 
(1996 in Germany and 1999 in Bologna at the third World 
Congress on Alternatives and Animal Use in the life Sciences) 
led to a declaration toward Good Cell Culture Practice – GCCP 
(Gstraunthaler and Hartung, 1999):
“The participants … call on the scientific community to 
develop guidelines defining minimum standards in cell and 
tissue culture, to be called Good Cell Culture Practice … 
should facilitate the interlaboratory comparability of in 
vitro results … encourage journals in the life sciences to 
adopt these guidelines...”
A GCCP task force was then established, which produced two 
reports (Hartung et al., 2002; Coecke et al., 2005). the main-
tenance of high standards is fundamental to all good scientific 
practice, and it is essential for ensuring the reproducibility, reli-
ability, credibility, acceptance, and proper application of any re-
sults produced. the aim of GCCP is to reduce uncertainty in the 
development and application of in vitro procedures by encour-
aging the establishment of principles for the greater internation-
al harmonization, standardization, and rational implementation 
of laboratory practices, nomenclature, quality control systems, 
safety procedures, and reporting, linked, where appropriate, to 
the application of the principles of Good laboratory Practice 
(GlP). GCCP addresses issues related to:





– education and training
– ethics
the GCCP documents formed a major basis for a GlP advisory 
document by OeCD for in vitro studies (OeCD, 2004), which 
addresses: 
– test Facility Organization and Personnel
– Quality Assurance Program
– Facilities
– Apparatus, Materials, and Reagents
– test Systems
– test and Reference Items
– Standard Operating Procedures
– Performance of the Study
– Reporting of Study Results
– Storage and Retention of Records and Materials
therefore, both guidance documents have a lot in common: In-
herent variation of in vitro test systems calls for standardization, 
and both the GlP advisory document and the GCCP guidance 
are intended to support best practice in all aspects of the use of 
in vitro systems, including the use of cells and tissues. When 
comparing GlP and GCCP, there also are some major differ-
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al test” or “gold standard.” For MCM we have neither human 
data, other drugs for the same purpose, nor established animal 
tests fit for purpose. A 2008 workshop (Hoffmann et al., 2008) 
discussed similar issues for toxicology, identifying three types 
of reference points: reference method/results where available; 
expert consensus to establish a putative point of reference 
where data are ambiguous and incomplete; and cases of no 
point of reference methods, such as latent class analysis. As 
laid out earlier (Hartung, 2010b), in the absence of reference 
data, the scientific validation needs to be stressed. Figure 1 
shows the classical validation scheme and its adaptation to 
such situations. The process of defining the point of reference 
for MCM evaluation will be very challenging. It should be 
started early enough, as it will guide test development, but it 
out major decrease in statistical power (Hoffmann and Hartung, 
2006). last, the introduction of performance standards, i.e., 
minimum criteria to be fulfilled for any later test development to 
prove equivalence to the validated test, represents a key tool to 
open the market for competing developments while also accom-
modating changes to the validated protocol without embarking 
on a full validation study.
It became evident, however, that it is difficult to adapt these 
schemes to such complex technologies as toxicogenomics 
(Corvi et al., 2006). therefore, the concept of applying some 
tools of evidence-based medicine for validation purposes was 
put forward (Hartung, 2010b). A key problem for the new 
technologies, and also for new products like MCM and end-
points, is the absence of a point of reference, i.e., a “tradition-
Fig. 1: The traditional validation scheme and its adaptation to situations without reference test
Hartung and Zurlo
Altex 29, 3/12258
grated testing strategies (ItS) or pathway-based approaches, as 
suggested in the roadmap for systemic toxicity testing (Hartung 
and McBride, 2011; Basketter et al., 2012) to produce more 
predictive systems. the last article in this Food for thought … 
series (Hartung et al., 2012) laid out the vision of a systems 
toxicology. Similarly, a systems pharmacology (van der Greef 
and McBurney, 2005; Berger and Iyengar, 2011; Hansen et al., 
2012) can be envisioned and is currently emerging to model 
drug interventions in the organism. In both cases it will be nec-
essary to convince the regulatory community to base decisions 
on this novel type of data, which will be best achieved by sci-
entific rigor and the continuous exposure to new evidence from 
opinion leaders and market forces.
A very interesting opportunity lies in making use of the new 
organotypic models for pathway identification. If the improved 
culture conditions boost relevance of the models, the pathway 
identification in these models should be even more relevant. 
Conclusions
the new interest in predictive in vitro systems in the US will re-
vamp the field of alternative approaches. The substantial funding 
opportunities will bring researchers and engineers into the field. 
It will be important to acquaint them with the lessons learned 
over the last two decades of developing predictive models and 
their quality assurance. toxicology has served as a pilot, but all 
areas of life sciences have similar needs, and drug development 
can benefit in similar ways.
While the Human on a Chip approach is not the only way 
to construct novel predictive test strategies, it complements 
approaches based on integrated testing strategies or pathway-
based approaches as they are mainly pursued in toxicology 
(tox-21c).
The validation process as defined originally by ECVAM has 
been proven to work. the eCVAM principles on validation 
were taken up by ICCVAM (USA) and internationally by the 
OeCD in GD 34 on the validation and international acceptance 
of new or updated test methods for hazard assessment. they 
can be reasonably translated to drug development purposes. the 
validation process is in constant evolution, and MCM will need 
such adaptations. Validation of tests is an essential quality as-
surance process, similar to eBM. the evidence-based toxicol-
ogy Collaboration (eBtC) promises to be a tool for validation 
of 21st century methods. 
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